GLPwatch
Add-on value of tirzepatide versus semaglutide.
Lancet Diabetes Endocrinol · 2022
Last updated 2026-09-22| Journal | Lancet Diabetes Endocrinol, 2022 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 0.47 |
| NIH percentile | 28 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity |
Full record and abstract on PubMed 35468323 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.